{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:27Z","timestamp":1788416007746,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"\n Background<\/jats:title>\n Rituximab (RTX) has been associated with immediate hypersensitivity reactions (HSRs) involving multiple phenotypes and endotypes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize the clinical phenotypes and endotypes of immediate RTX HSRs.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A prospective study was conducted as part of a pharmacovigilance program from July 2020 to December 2021. Participants who experienced immediate RTX HSRs were enrolled. Skin testing, basophil activation testing (BAT), IFN-\n \u03b3<\/jats:italic>\n ELISpot assays, and IgG anti-drug antibody (ADA) ELISA assays were performed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seventeen patients with immediate RTX reaction were enrolled, including 9 with infusion-related reactions (IRRs) and 8 with immediate RTX HSRs. Among 13 patients who underwent biomarkers testing, all 5 patients with IRRs showed negative result for all biomarkers. Among the eight patients with immediate RTX HSRs, elevated serum tryptase levels during acute reaction onset were observed in four patients, suggesting possible type I reaction, although definite classification was limited by the reaction. Two of the 8 patients demonstrated elevated IL-6 levels together with increased serum tryptase levels, suggesting mixed reactions (type I\/CRS). The remaining 4 patients could not be assigned to a specific endotype and were therefore categorized as unclassified. BAT results were negative in all cases.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Immediate RTX HSRs demonstrated heterogeneous phenotypes and endotypes. IRRs were the most common phenotype and occurred exclusively during the first RTX cycle. Skin testing, ADA detection, and serum IL-6 measurement may contribute to endotype characterization, although larger prospective studies are needed to establish their diagnostic utility.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/falgy.2026.1903523","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:29Z","timestamp":1788412949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical phenotypes, endotypes, and biomarker profiles of immediate rituximab hypersensitivity reactions: a prospective pharmacovigilance study"],"prefix":"10.3389","volume":"7","author":[{"given":"Narapong","family":"Yotinnoratham","sequence":"first","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wannada","family":"Laisuan","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumutnart","family":"Chanprapaph","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silada","family":"Kanokrungsee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavachol","family":"Setthaudom","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supornchai","family":"Onpun","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pungjai","family":"Mongkolpathumrat","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Center of Excellence for Skin and Allergy Research, Faculty of Medicine, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supranee","family":"Buranapraditkun","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Center of Excellence for Skin and Allergy Research, Faculty of Medicine, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Chungcharoenpanich","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichapha","family":"Dechapaphapitak","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supa","family":"Oncham","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattakirana","family":"Tongdee","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sananya","family":"Khamkaew","sequence":"additional","affiliation":[{"name":"Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratchaya","family":"Lertnawapan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Thammasat University","place":["Pathumthani, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jettanong","family":"Klaewsongkram","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Center of Excellence for Skin and Allergy Research, Faculty of Medicine, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22799036261427948","DOI":"10.1177\/22799036261427948","article-title":"Descriptive analysis of anaphylactic events reported in the FDA adverse event reporting system (FAERS)","volume":"15","author":"Jaser Ahmed","year":"2026","journal-title":"J Public Health Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000478077","article-title":"The immunogenicity of biologic therapies","volume":"53","author":"Garces","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents-updated diagnosis, management, and treatment","volume":"3","author":"Galvao","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/all.16576","article-title":"Endotypes in immune mediated drug reactions: present and future of relevant biomarkers. An EAACI task force report","volume":"80","author":"Mayorga","year":"2025","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12016-016-8556-5","article-title":"Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies","volume":"54","author":"Bonamichi-Santos","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E130","DOI":"10.1002\/ajh.23329","article-title":"Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test","volume":"87","author":"Piva","year":"2012","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/jdv.14890","article-title":"The measurement of drug-induced interferon gamma-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions","volume":"32","author":"Suthumchai","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4231561","DOI":"10.1155\/2020\/4231561","article-title":"Assessment of confirmed clinical hypersensitivity to rituximab in patients affected with B-cell neoplasia","volume":"2020","author":"Novelli","year":"2020","journal-title":"Adv Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaci.2017.06.012","article-title":"Diagnosis and management of anaphylaxis in precision medicine","volume":"140","author":"Castells","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fphar.2016.00171","article-title":"Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations","volume":"7","author":"Steiner","year":"2016","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-021-00429-9","article-title":"Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients","volume":"7","author":"Awasthi","year":"2021","journal-title":"Cell Death Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-023-00584-8","article-title":"Severe hypersensitivity reactions at biosimilar versus originator rituximab treatment initiation, switch and over time: a cohort study on the French national health data system","volume":"37","author":"Jourdain","year":"2023","journal-title":"BioDrugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1007\/s12325-020-01472-1","article-title":"The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence","volume":"37","author":"Feagan","year":"2020","journal-title":"Adv Ther"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1903523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:30Z","timestamp":1788412950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1903523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":23,"alternative-id":["10.3389\/falgy.2026.1903523"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1903523","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1903523"}}